康缘药业(600557.SH)：金振口服液增加适应症获得临床试验批准通知书

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) has received approval from the National Medical Products Administration for a new indication of its Jin Zhen Oral Liquid for treating children's influenza (heat toxin attacking the lung syndrome) [1] Company Summary - Jin Zhen Oral Liquid is a proprietary traditional Chinese medicine developed by the company, consisting of eight ingredients including goat horn, Pingbei mother, Huangqin, and Dahuang [1] - The product was granted a new drug certificate and production license in 1997 and is included in the National Essential Medicines List and the National Medical Insurance Directory [1] - It is also listed in the 2025 edition of the "Chinese Pharmacopoeia" and represents the company's product line for respiratory and infectious diseases [1] - The company has invested approximately 2.69 million yuan in the research and development of the new indication for Jin Zhen Oral Liquid [1] Industry Summary - The new indication for Jin Zhen Oral Liquid targets influenza, a respiratory infectious disease caused by the influenza virus [1] - Pharmacological studies indicate that Jin Zhen Oral Liquid significantly reduces the viral load in lung tissue and improves lung index elevation caused by viral infection [1] - Toxicological studies from GLP laboratories show that the drug has good safety [1] - Clinical efficacy observations have demonstrated significant effectiveness of Jin Zhen Oral Liquid in alleviating symptoms such as cough, phlegm, and fever caused by influenza in children [1]